ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
Date: | Thursday, February 27, 2025 |
Time: | 3:30 p.m. CST / 4:30 p.m. EST |
Location: | |
U.S. dial-in | +1 (800) 715-9871 |
International dial-in: | +1 (646) 307-1963 |
Conference ID: | 6342275 |
A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures, will be available on the Investor Relations section of Solventum's website.
Other upcoming Investor Events:
2025 Investor Day | Mid-March (location: NYC) Additional details to follow |
Solventum plans to host an Investor Day in March in New York City to introduce its strategy to accelerate growth and its long-range financial plan. More details and registration information will be shared soon.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

| Last Trade: | US$76.19 |
| Daily Change: | 0.53 0.70 |
| Daily Volume: | 975,281 |
| Market Cap: | US$13.220B |
November 06, 2025 October 21, 2025 August 07, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load